Statin-mediated protective effects in the central nervous system: General mechanisms and putative role of stress proteins

Restorative Neurology and Neuroscience

Volumn 24, Issue 2, 2006, Pages 79-95

  Schmeer, Christian ^a   Kretz, Alexandra ^a   Isenmann, Stefan ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Atherosclerosis; Neurodegeneration; Neuroprotection; Retina; Retinal diseases; Statins; Stroke

Indexed keywords

ATORVASTATIN; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; GAMMA INTERFERON; GLUCOSE REGULATED PROTEIN 78; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 72; HEAT SHOCK PROTEIN 73; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 2; LOW DENSITY LIPOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEVINOLIN; NEUROPROTECTIVE AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PRAVASTATIN; PROTEIN KINASE B; ROSUVASTATIN; SIMVASTATIN; VASCULOTROPIN;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; AXONAL INJURY; BRAIN INJURY; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; DIABETIC RETINOPATHY; DRUG MECHANISM; EYE DISEASE; HUMAN; IMMUNE RESPONSE; LIPID METABOLISM; LIPID OXIDATION; MEDLINE; MOOD DISORDER; MULTIPLE SCLEROSIS; MYALGIA; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHABDOMYOLYSIS; SIGNAL TRANSDUCTION; THROMBOCYTE FUNCTION;

ANIMALS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; HEAT-SHOCK PROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROTECTIVE AGENTS;

EID: 33646689805     PISSN: 09226028     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (174)

1. No authors listed, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet 344 (1994), 1383-1389.
2. No authors listed, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, N. Engl. J. Med. 339 (1998), 1349-1357.
3. No authors listed, Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group, Lancet 352 (1998), 1801-1807.
4. No authors listed, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet 360 (2002), 7-22.
5. No authors listed, Using Crestor - and all statins - safely, Harv. Heart Lett. 16 (2005), 3.
6. D.A. Aquino, E. Capello, J. Weisstein, V. Sanders, C. Lopez, W.W. Tourtellotte, C.F. Brosnan, C.S. Raine and W.T. Norton, Multiple sclerosis: altered expression of 70- and 27-kDa heat shock proteins in lesions and myelin, J. Neuropathol. Exp. Neurol. 56 (1997), 664-672.
7. O. Aktas, S. Waiczies, A. Smorodchenko, J. Dorr, B. Seeger, T. Prozorovski, S. Sallach, M. Endres, S. Brocke, R. Nitsch and F. Zipp, Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin, J. Exp. Med. 197 (2003), 725-733.
8. P. Ambrosi, P. Villani, G. Habib and G. Bouvenot, The statins: new properties, Therapie 58 (2003), 15-21.
9. D.H. Anderson, K.C. Talaga, A.J. Rivest, E. Barron, G.S. Hageman and L.V. Johnson, Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration, Exp. Eye Res. 78 (2004), 243-256.
10. M. Asahi, Z. Huang, S. Thomas, S. Yoshimura, T. Sumii, T. Mori, J. Qiu, S. Amin-Hanjani, P.L. Huang, J.K. Liao, E.H. Lo and M.A. Moskowitz, Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia, J. Cereb. Blood Flow Metab. 25 (2005), 722-729.
11. M. Aviram, M. Rosenblat, C.L. Bisgaier and R.S. Newton, Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation, Atherosclerosis 138 (1998), 271-280.
12. W.W. Barker, C.A. Luis, A. Kashuba, M. Luis, D.G. Harwood, D. Loewenstein, C. Waters, P. Jimison, E. Shepherd, S. Sevush, N. Graff-Radford, D. Newland, M. Todd, B. Miller, M. Gold, K. Heilman, L. Doty, I. Goodman, B. Robinson, G. Pearl, D. Dickson and R. Duara, Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank, Alzheimer Dis. & Assoc. Disord. 16 (2002), 203-212.
13. G. Basta, A.M. Schmidt and R. De Caterina, Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes, Cardiovasc. Res. 63 (2004), 582-592.
14. L. Battistini, M. Salvetti, G. Ristori, M. Falcone, C.S. Raine and C.F. Brosnan, Gamma delta T cell receptor analysis supports a role for Hsp70 selection of lymphocytes in multiple sclerosis lesions, 1 (1995), 554-562.
15. H.M. Beere, B.B. Wolf, K. Cain, D.D. Mosser, A. Mahboudi, T. Kuwana, P. Tailor, R.I. Morimoto, G.M. Cohen and D.R. Green, Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome, Nat. Cell Biol. 2 (2000), 469-475.
16. H.M. Beere, "The stress of dying": the role of heat shock proteins in the regulation of apoptosis, J. Cell Sci. 117 (2004), 2641-2651.
17. S. Bellosta, R. Paoletti and A. Corsini, Safety of statins: focus on clinical pharmacokinetics and drug interactions, Circulation 109 (2004), III50-57.
18. J. Beltowski, G. Wojcicka and A. Jamroz, Effect of 3-hydroxy-3- methylglutarylcoenzyme A reductase inhibitors (statins) on tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities, J. Cardiovasc. Pharmacol. 43 (2004), 121-127.
19. R. Benfante, K. Yano, L.J. Hwang, J.D. Curb, A. Kagan and W. Ross, Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk, Stroke 25 (1994), 814-820.
20. G. Birnbaum, Stress proteins: their role in the normal central nervous system and in disease states, especially multiple sclerosis, Springer Semin. Immunopathol. 17 (1995), 107-118.
21. G. Birnbaum and L. Kotilinek, Heat shock or stress proteins and their role as autoantigens in multiple sclerosis, Ann. N. Y. Acad. Sci. 835 (1997), 157-167.
22. D.M. Black, R.G. Bakker-Arkema and J.W. Nawrocki, An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor, Arch. Intern. Med. 158 (1998), 577-584.
23. M. Brines and A. Cerami, Emerging biological roles for erythropoietin in the nervous system, Nat. Rev. Neurosci. 6 (2005), 484-494.
24. A. Brouet, P. Sonveaux, C. Dessy, S. Moniotte, J.L. Balligand and O. Feron, Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins, Circ. Res. 89 (2001), 866-873.
25. M.S. Brown and J.L. Goldstein, Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth, J Lipid Res. 21 (1980), 505-517.
26. S.J. Charette, J.N. Lavoie, H. Lambert and J. Landry, Inhibition of Daxx-mediated apoptosis by heat shock protein 27, Mol. Cell. Biol. 20 (2000), 7602-7612.
27. J. Chen, Z.G. Zhang, Y. Li, Y. Wang, L. Wang, H. Jiang, C. Zhang, M. Lu, M. Katakowski, C.S. Feldkamp and M. Chopp, Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke, Ann. Neurol. 53 (2003), 743-751.
28. J. Chen, C. Zhang, H. Jiang, Y. Li, L. Zhang, A. Robin, M. Katakowski, M. Lu and M. Chopp, Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice, J. Cereb. Blood Flow Metab. 25 (2005), 281-290.
29. A. Chiloeches, F. Usera, M. Lasa, S. Ropero, A. Montes and M.J. Toro, Effect of mevalonate availability on the association of G-protein alpha-subunits with the plasma membrane in GH4C1 cells, FEBS Lett. 401 (1997), 68-72.
30. M. Chopp, The roles of heat shock proteins and immediate early genes in central nervous system normal function and pathology, Curr. Opin. Neurol. Neurosurg. 6 (1993), 6-10.
31. R. Collins, J. Armitage, S. Parish, P. Sleight and R. Peto, Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions, Lancet 363 (2004), 757-767.
32. E.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, G.W. Small, A.D. Roses, J.L. Haines and M.A. Pericak-Vance, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science 261 (1993), 921-923.
33. M. Crisby, G. Nordin-Fredriksson, P.K. Shah, J. Yano, J. Zhu and J. Nilsson, Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization, Circulation 103 (2001), 926-933.
34. M.H. Davidson, Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust, Drugs 61 (2001), 197-206.
35. J. Davignon and P. Ganz, Role of endothelial dysfunction in atherosclerosis, Circulation 109 (2004), III27-32.
36. W. Dichtl, J. Dulak, M. Frick, H.F. Alber, S.P. Schwarzacher, M.P. Ares, J. Nilsson, O. Pachinger and F. Weidinger, HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells, Arteioscler. Thromb. Vasc. Biol. 23 (2003), 58-63.
37. R. Diem, R. Meyer, J.H. Weishaupt and M. Bahr, Reduction of potassium currents and phosphatidylinositol 3-kinase-dependent AKT phosphorylation by tumor necrosis factor-(alpha) rescues axotomized retinal ganglion cells from retrograde cell death in vivo, J. Neurosci 21 (2001), 2058-2066.
38. R. Diem, M. Hobom, K. Maier, R. Weissert, M.K. Storch, R. Meyer and M. Bahr, Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway, J. Neurosci. 23 (2003), 6993-7000.
39. J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, A. Langendorfer, E.A. Stein, W. Kruyer and A. M. Gotto Jr., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study, JAMA 279 (1998), 1615-1622.
40. M. Endoh, K. Maiese and J. Wagner, Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global ischemia, Brain. Res. 651 (1994), 92-100.
41. M. Endres, U. Laufs, Z. Huang, T. Nakamura, P. Huang, M.A. Moskowitz and J.K. Liao, Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase, Proc. Natl. Acad. Sci. USA 95 (1998), 8880-8885.
42. M. Eyries, T. Collins and L.M. Khachigian, Modulation of growth factor gene expression in vascular cells by oxidative stress, Endothelium 11 (2004), 133-139.
43. K. Fassbender, M. Simons, C. Bergmann, M. Stroick, D. Lutjohann, P. Keller, H. Runz, S. Kuhl, T. Bertsch, K. von Bergmann, M. Hennerici, K. Beyreuther and T. Hartmann, Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo, Proc. Natl. Acad. Sci. USA 98 (2001), 5856-5861.
44. C. Forster, H.B. Clark, M.E. Ross and C. Iadecola, Inducible nitric oxide synthase expression in human cerebral infarcts, Acta Neuropathol. (Berl) 97 (1999), 215-220.
45. T.F. Franke, S.I. Yang, T.O. Chan, K. Datta, A. Kazlauskas, D.K. Morrison, D.R. Kaplan and P.N. Tsichlis, The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase, Cell 81 (1995), 727-736.
46. M. Friedman, T.E. Fitch and W.E. Yokoyama, Lowering of plasma LDL cholesterol in hamsters by the tomato glycoalkaloid tomatine, Food Chem. Toxicol. 38 (2000), 549-553.
47. V. Gaddam, D.Y. Li and J.L. Mehta, Anti-thrombotic effects of atorvastatin - an effect unrelated to lipid lowering, J. Cardiovasc. Pharmacol. Ther. 7 (2002), 247-253.
48. C. Garrido, J.M. Bruey, A. Fromentin, A. Hamman, A.P. Arrigo and E. Solary, Hsp27 inhibits cytochrome c-dependent activation of procaspase-9, FASEB J. 13 (1999), 2061-2070.
49. Y.L. Gao, C.F. Brosnan and C.S. Raine, Experimental autoimmune encephalomyelitis. Qualitative and semiquantitative differences in heat shock protein 60 expression in the central nervous system, J. Immunol. 154 (1995), 3548-3556.
50. M. Ghayour-Mobarhan, D.J. Lamb, N. Vaidya, C. Livingstone, T. Wang and G.A. Ferns, Heat shock protein antibody titers are reduced by statin therapy in dyslipidemic subjects: a pilot study, Angiology 56 (2005), 61-68.
51. J.A. Glomset, M.H. Gelb and C.C. Farnsworth, Prenyl proteins in eukaryotic cells: a new type of membrane anchor, Trends Biochem. Sci. 15 (1990), 139-142.
52. J.L. Goldstein and M.S. Brown, Regulation of the mevalonate pathway, Nature 343 (1990), 425-430.
53. B. Gordon, S. Chang, M. Kavanagh, M. Berrocal, L. Yannuzzi, C. Robertson and A. Drexler, The effects of lipid lowering on diabetic retinopathy, Am. J. Ophthalmol. 112 (1991), 385-391.
54. J. Greenwood, C.E. Walters, G. Pryce, N. Kanuga, E. Beraud, D. Baker and P. Adamson, Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis, Faseb J. 17 (2003), 905-907.
55. O. Grip, S. Janciauskiene and S. Lindgren, Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes, Inflamm. Res. 51 (2002), 58-62.
56. A. Gupta, V. Gupta, S. Thapar and A. Bhansali, Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema, Am. J. Ophthalmol. 137 (2004), 675-682.
57. R.H. Guymer, A.W. Chiu, L. Lim and P.N. Baird, HMG CoA reductase inhibitors (statins): do they have a role in age-related macular degeneration? Surv. Ophthalmol. 50 (2005), 194-206.
58. G.S. Hageman, P.J. Luthert, N.H. Victor Chong, L.V. Johnson, D.H. Anderson and R.F. Mullins, An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration, Prog. Retin Eye Res. 20 (2001), 705-732.
59. J.E. Hamos, B. Oblas, D. Pulaski-Salo, W.J. Welch, D.G. Bole and D.A. Drachman, Expression of heat shock proteins in Alzheimer's disease, Neurology 41 (1991), 345-350.
60. G.K. Hansson, Inflammation and immune response in atherosclerosis, Curr. Atheroscler. Rep. 1 (1999), 150-155.
61. E. Hara, K. Takahashi, T. Tominaga, T. Kumabe, T. Kayama, H. Suzuki, H. Fujita, T. Yoshimoto, K. Shirato and S. Shibahara, Expression of heme oxygenase and inducible nitric oxide synthase mRNA in human brain tumors, Biochem. Biophys. Res. Commun. 224 (1996), 153-158.
62. M.B. Harris, M.A. Blackstone, S.G. Sood, C. Li, J.M. Goolsby, V.J. Venema, B.E. Kemp and R.C. Venema, Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors, Am. J Physiol Heart. Circ. Physiol. 287 (2004), H560-H566.
63. M. Honjo, H. Tanihara, K. Nishijima, J. Kiryu, Y. Honda, B.Y. Yue and T. Sawamura, Statin inhibits leukocyte-endothelial interaction and prevents neuronal death induced by ischemia-reperfusion injury in the rat retina, Arch. Ophthalmol. 120 (2002), 1707-1713.
64. J.N. Housby, C.M. Cahill, B. Chu, R. Prevelige, K. Bickford, M.A. Stevenson and S.K. Calderwood, Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes, Cytokine 11 (1999), 347-358.
65. T. Ichiki, K. Takeda, T. Tokunou, N. Iino, K. Egashira, H. Shimokawa, K. Hirano, H. Kanaide and A. Takeshita, Down-regulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells, Arterioscler. Thromb. Vasc. Biol. 21 (2001), 1896-1901.
66. L.J. Ignarro and C. Napoli, Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis, Curr. Diab. Rep. 5 (2005), 17-23.
67. H. Iso, D.R. Jacobs Jr., D. Wentworth, J.D. Neaton and J.D. Cohen, Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial, N. Engl. J. Med. 320 (1989), 904-910.
68. H. Ito, K. Hasegawa, Y. Inaguma, O. Kozawa and K. Kato, Enhancement of stress-induced synthesis of hsp27 and alpha B crystallin by modulators of the arachidonic acid cascade, J. Cell. Physiol. 166 (1996), 332-339.
69. M. Jäättelä, D. Wissing, K. Kokholm, T. Kallunki and M. Egeblad, Hsp70 exerts ist anti-apoptotic function downstream of caspase-3-like proteases, EMBO J. 17 (1998), 6124-6134.
70. H. Jick, G.L. Zornberg, S.S. Jick, S. Seshadri and D.A. Drachman, Statins and the risk of dementia, Lancet 356 (2000), 1627-1631.
71. J. Joles, N. Willekes-Koolschijn, H. Koomans, A. Van Tol, T. Geelhoed-Mieras, D. Crommelin, L. Van Bloois et al., Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats, Lab. Anim. 26 (1992), 269-280.
72. D.B. Jones, A.F. Coulson and G.W. Duff, Sequence homologies between hsp60 and autoantigens, Immunol. Today 14 (1993), 115-118.
73. S.A. Kalwy, M.T. Akbar, R.S. Coffin, J. de Belleroche and D.S. Latchman, Heat shock protein 27 delivered via a herpes simplex virus vector can protect neurons of the hippocampus against kainic-acid-induced cell loss, Brain. Res. Mol. Brain Res. 111 (2003), 91-103.
74. M. Kamiyama, K. Utsunomiya, K. Taniguchi, T. Yokota, H. Kurata, N. Tajima and K. Kondo, Contribution of Rho A and Rho kinase to platelet-derived growth factor-BB-induced proliferation of vascular smooth muscle cells, J. Atheroscler. Thromb 10 (2003), 117-123.
75. P. Kermer, N. Klocker, M. Labes and M. Bahr, Insulin-like growth factor-I protects axotomized rat retinal ganglion cells from secondary death via PI3-K-dependent Akt phosphorylation and inhibition of caspase-3 In vivo, J. Neurosci. 20 (2000), 2-8.
76. R.N. Khurana, R.L. Maddala, H. Shimokawa, J. Samuel Zigler, D.L. Epstein and P. Vasantha Rao, Inhibition of Rho-kinase induces alphaB-crystallin expression in lens epithelial cells, Biochem. Biophys. Res. Commun. 294 (2002), 981-987.
77. Y. Kitamura and Y. Nomura, Stress proteins and glial functions: possible therapeutic targets for neurodegenerative disorders, Pharmacol. Ther. 97 (2003), 35-53.
78. C.C. Klaver, J.J. Assink, R. van Leeuwen, R.C. Wolfs, J.R. Vingerling, T. Stijnen, A. Hofman and P.T. de Jong, Incidence and progression rates of age-related maculopathy: the Rotterdam Study, Invest. Ophthalmol. & Vis. Sci. 42 (2001), 2237-2241.
79. A. Klettner and T. Herdegen, The immunophilin-ligands FK506 and V-10,367 mediate neuroprotection by the heat shock response, Br. J. Pharmacol. 138 (2003), 1004-1012.
80. A. Klettner, The induction of heat shock proteins as a potential strategy to treat neurodegenerative disorders, Drug News & Perspect. 17 (2004), 299-306.
81. E. Kojro, G. Gimpl, S. Lammich, W. Marz and F. Fahrenholz, Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. [see comment], Proc. Natl. Acad. Sci. USA 98 (2001), 5815-5820.
82. A. Kretz, C.J. Happold, J.K. Marticke and S. Isenmann, Erythropoietin promotes regeneration of adult CNS neurons via Jak2/Stat3 and PI3K/AKT pathway activation, Mol. Cell. Neurosci. (2005), (in press).
83. A. Kretz, C. Schmeer, S. Tausch and S. Isenmann, Simvastatin promotes heat shock protein 27 expression and Akt activation in the rat retina and protects axotomized retinal cells in vivo, Neurobiol. Dis. (2005), (in press).
84. T. Kudo, T. Katayama, K. Imaizumi, Y. Yasuda, M. Yatera, M. Okochi, M. Tohyama and M. Takeda, The unfolded protein response is involved in the pathology of Alzheimer's disease, Ann. N. Y. Acad. Sci. 977 (2002), 349-355.
85. Y. Kunieda, K. Nakagawa, H. Nishimura, H. Kato, N. Ukimura, S. Yano, H. Kawano, S. Kimura, M. Nakagawa and H. Tsuji, HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells, Thromb. Res. 110 (2003), 227-234.
86. Y. Kureishi, Z. Luo, I. Shiojima, A. Bialik, D. Fulton, D.J. Lefer, W.C. Sessa and K. Walsh, The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals, Nat. Med. 6 (2000), 1004-1010.
87. B. Kwak, F. Mulhaupt, S. Myit and F. Mach, Statins as a newly recognized type of immunomodulator, Nat. Med. 6 (2000), 1399-1402.
88. J. C. LaRosa, J. He and S. Vupputuri, Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials, JAMA 282 (1999), 2340-2346.
89. U. Laufs, S. Wassmann, S. Hilgers, N. Ribaudo, M. Bohm and G. Nickenig, Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men, Am. J. Cardiol. 88 (2001), 1306-1307.
90. U. Laufs, K. Gertz, U. Dirnagl, M. Bohm, G. Nickenig and M. Endres, Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice, Brain Res. 942 (2002), 23-30.
91. S.H. Lee, H.M. Kwon, Y.J. Kim, K.M. Lee, M. Kim and B.W. Yoon, Effects of hsp70.1 gene knockout on the mitochondrial apoptotic pathway after focal cerebral ischemia, Stroke 35 (2004), 2195-2199.
92. G.N. Levine, J.F. Keaney Jr. and J.A. Vita, Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms, N. Engl. J. Med. 332 (1995), 512-521.
93. S.E. Lewis, R.J. Mannion, F.A. White, R.E. Coggeshall, S. Beggs, M. Costigan, J.L. Martin, W.H. Dillmann and C.J. Woolf, A role for HSP27 in sensory neuron survival, J. Neurosci. 19 (1999), 8945-8953.
94. J.J. Li and X.J. Chen, Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide, Coron. Artery Dis. 14 (2003), 329-334.
95. J.K. Liao, Isoprenoids as mediators of the biological effects of statins, J. Clin. Invest. 110 (2002), 285-288.
96. G.P. Lim, F. Yang, T. Chu, E. Gahtan, O. Ubeda, W. Beech, J.B. Overmier, K. Hsiao-Ashec, S.A. Frautschy and G.M. Cole, Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice, Neurobiol. Aging 22 (2001), 983-991.
97. J.S. Liu, M.L. Zhao, C.F. Brosnan and S.C. Lee, Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions, Am. J. Pathol. 158 (2001), 2057-2066.
98. S. Locatelli, D. Lutjohann, H.H. Schmidt, C. Otto, U. Beisiegel and K. von Bergmann, Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain, Arch. Neurol. 59 (2002), 213-216.
99. C. Mailhos, M.K. Howard and D.S. Latchman, Heat shock protects neuronal cells from programmed cell death by apoptosis, Neuroscience 55 (1993), 621-627.
100. W.A. Maltese, Posttranslational modification of proteins by isoprenoids in mammalian cells, Faseb J. 4 (1990), 3319-3328.
101. H. Mangge, H. Hubmann, S. Pilz, K. Schauenstein, W. Renner and W. Marz, Beyond cholesterol - inflammatory cytokines, the key mediators in atherosclerosis, Clin. Chem. Lab. Med. 42 (2004), 467-474.
102. D. Martin, M. Salinas, R. Lopez-Valdaliso, E. Serrano, M. Recuero and A. Cuadrado, Effect of the Alzheimer amyloid fragment Abeta(25-35) on Akt/PKB kinase and survival of PC12 cells, J. Neurochem. 78 (2001), 1000-1008.
103. J.C. Mason, Statins and their role in vascular protection, Clin. Sci (Lond) 105 (2003), 251-266.
104. C.A. McCarty, B.N. Mukesh, C.L. Fu, P. Mitchell, J.J. Wang and H.R. Taylor, Risk factors for age-related maculopathy: the Visual Impairment Project, Arch. Ophthalmol. 119 (2001), 1455-1462.
105. G. McGwin Jr., C. Owsley, C.A. Curcio and R.J. Crain, The association between statin use and age related maculopathy, Br. J. Ophthalmol. 87 (2003), 1121-1125.
106. G. McGwin Jr., S. McNeal, C. Owsley, C. Girkin, D. Epstein and P.P. Lee, Statins and other cholesterol-lowering medications and the presence of glaucoma, Arch. Ophthalmol. 122 (2004), 822-826.
107. K.M. Mearow, M.E. Dodge, M. Rahimtula and C. Yegappan, Stress-mediated signaling in PC12 cells - the role of the small heat shock protein, Hsp27, and Akt in protecting cells from heat stress and nerve growth factor withdrawal, J. Neurochem. 83 (2002), 452-462.
108. T. Miida, S. Hirayama and Y. Nakamura, Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia, J. Atheroscler. Thromb. 11 (2004), 253-264.
109. P.J. Miranda, R.A. DeFronzo, R.M. Califf and J.R. Guyton, Metabolic syndrome: definition, pathophysiology, and mechanisms, Am. Heart J. 149 (2005), 33-45.
110. M.T. Montera, O. Hernandez, Y. Suarez, J. Mantilla, A.J. Ferruelo, J. Martinez-Botas, D. Gomez-Coronado and M.A. Lasuncion, Hydroxymethylglutaryl- coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells, Atherosclerosis 153 (2000), 303-313.
111. P.R. Moreno and V. Fuster, New aspects in the pathogenesis of diabetic atherothrombosis, J. Am. Coll. Cardiol. 44 (2004), 2293-2300.
112. D.D. Mosser, A.W. Caron, L. Bourget, A.B. Meriin, M.Y. Sherman, R.I. Morimoto and B. Massie, The chaperone function of Hsp70 is required for protection against stress-induced apoptosis, Mol. Cell Biol. 20 (2000), 7146-7159.
113. J. Nawarskas, HMG-CoA reductase inhibitors and coenzyme Q10, Cardiol. Rev. 13 (2005), 76-79.
114. P. Negre-Aminou, R.E. van Leeuwen, G.C. van Thiel, I.P. van den, W.W. de Jong, R.A. Quinlan and L.H. Cohen, Differential effect of simvastatin on activation of Rac(1) vs. activation of the heat shock protein 27-mediated pathway upon oxidative stress, in human smooth muscle cells, Biochem. Pharmacol. 64 (2002), 1483-1491.
115. O. Neuhaus, S. Strasser-Fuchs, F. Fazekas, B.C. Kieseier, G. Niederwieser, H.P. Hartung and J.J. Archelos, Statins as immunomodulators: comparison with interferon-beta 1b in MS, Neurol. 59 (2002), 990-997.
116. O. Neuhaus, O. Stuve, S.S. Zamvil and H.P. Hartung, Are statins a treatment option for multiple sclerosis? Lancet Neurol. 3 (2004), 369-371.
117. J. Nylandsted, M. Rohde, K. Brand, L. Bastholm, F. Elling and M. Jäättelä, Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death programm that is independent of caspases and bypasses Bcl-2, Proc. Natl. Acad. Sci. USA 97 (2000), 7871-7876.
118. K. Ohtsuka and T. Suzuki, Roles of molecular chaperones in the nervous system, Brain. Res. Bull. 53 (2000), 141-146.
119. K. Pahan, F.G. Sheikh, A.M. Namboodiri and I. Singh, Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages, J. Clin. Invest. 100 (1997), 2671-2679.
120. A.S. Paintlia, M.K. Paintlia, A.K. Singh, R. Stanislaus, A.G. Gilg, E. Barbosa and I. Singh, Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin, J. Neurosci. Res. 77 (2004), 63-81.
121. A. Papassotiropoulos, D. Lutjohann, M. Bagli, S. Locatelli, F. Jessen, M.L. Rao, W. Maier, I. Bjorkhem, K. von Bergmann and R. Heun, Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease, Neuroreport 11 (2000), 1959-1962.
122. P.L. Penfold, M.C. Madigan, M.C. Gillies and J.M. Provis, Immunological and aetiological aspects of macular degeneration, Prog. Retin. Eye Res. 20 (2001), 385-414.
123. N. Perez, J. Sugar, S. Charya, G. Johnson, C. Merril, L. Bierer, D. Perl, V. Haroutunian and W. Wallace, Increased synthesis and accumulation of heat shock 70 proteins in Alzheimer's disease, Brain Res. Mol. Brain Res. 11 (1991), 249-254.
124. S.J. Pittler, S.J. Fliesler and L.M. Rapp, Novel morphological changes in rat retina induced by intravitreal injection of lovastatin, Exp. Eye Res. 54 (1992), 149-152.
125. J.N. Poynter, S.B. Gruber, P.D. Higgins, R. Almog, J.D. Bonner, H.S. Rennert, M. Low, J.K. Greenson and G. Rennert, Statins and the risk of colorectal cancer, N. Engl. J. Med. 352 (2005), 2184-2192.
126. C.S. Raine, E. Wu, J. Ivanyi, D. Katz and C.F. Brosnan, Multiple sclerosis: a protective or a pathogenic role for heat shock protein 60 in the central nervous system? Lab. Invest. 75 (1996), 109-123.
127. T.D. Rea, J.C., Breitner, B.M. Psaty, A.L. Fitzpatrick, O.L. Lopez, A.B. Newman, W.R. Hazzard, P.P. Zandi, G.L. Burke et al., Statin use and the risk of incident dementia: the Cardiovascular Health Study, Arch. Neurol. 62 (2005), 1047-1051.
128. K. Renkawek, G.J. Bosman and W.W. de Jong, Expression of small heat-shock protein hsp 27 in reactive gliosis in Alzheimer disease and other types of dementia, Acta Neuropathol. (Berl). 87 (1994), 511-519.
129. M. Romano, L. Diomede, M. Sironi, L. Massimiliano, M. Sottocorno, N. Polentarutti, A. Guglielmotti, D. Albani, A. Bruno, P. Fruscella, M. Salmona, A. Vecchi, M. Pinza and A. Mantovani, Inhibition of monocyte chemotactic protein-1 synthesis by statins, Lab. Invest. 80 (2000), 1095-1100.
130. T. Rundek, A. Naini, R., Sacco, K. Coates and S. DiMauro, Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke, Arch Neurol. 61 (2004), 889-892.
131. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, L. Brown, J.W. Warnica, J.M. Arnold, C.C. Wun, B.R. Davis and E. Braunwald, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators, N. Engl. J. Med. 335 (1996), 1001-1009.
132. A. Samali and T.G. Cotter, Heat shock proteins increase resistance to apoptosis, Exp. Cell Res. 223 (1996), 163-170.
133. M.B. Sattler, R. Diem, D. Merkler, I. Demmer, I. Boger, C. Stadelmann and M. Bahr, Simvastatin treatment does not protect retinal ganglion cells from degeneration in a rat model of autoimmune optic neuritis, Exp. Neurol. 193 (2005), 163-171.
134. K. Sen, A. Misra, A. Kumar and R.M. Pandey, Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia, Diabetes Res. Clin. Pract. 56 (2002), 1-11.
135. A. Sena, R. Pedrosa and M.G. Morais, Statins for multiple sclerosis, Lancet 364 (2004), 412; author reply 412-413.
136. P.X. Shaw, Rethinking oxidized low-density lipoprotein, its role in atherogenesis and the immune responses associated with it, Arch. Immunol. Ther. Exp. (Warsz) 52 (2004), 225-239.
137. J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. MacFarlane, J.H. McKillop and C.J. Packard, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group, N. Engl. J. Med. 333 (1995), 1301-1307.
138. M. Simons, P. Keller, B. De Strooper, K. Beyreuther, C.G. Dotti and K. Simons, Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons, Proc. Natl. Acad. Sci. USA 95 (1998), 6460-6464.
139. M. Simons, F. Schwarzler, D. Lutjohann, K. von Bergmann, K. Beyreuther, I. Dichgans, H. Wormstall, T. Hartmann and J. B. Schulz, Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial, Ann. Neurol. 52 (2002), 346-350.
140. I. Singh, A.S. Paintlia, M. Khan, R. Stanislaus, M.K. Paintlia, E. Haq, A.K. Singh and M.A. Contreras, Impaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment, Brain. Res. 1022 (2004), 1-11.
141. D.E. Sparks, Intraneuronal beta-amyloid immunoreactivity in the CNS, Neurobiol. Aging 17 (1996), 291-299.
142. D.L. Sparks, M.N. Sabbagh, D.J. Connor, J. Lopez, L.J. Launer, S. Petanceska, P. Browne, D. Wassar et al., Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD, Curr. Alzheimer Res. 2 (2005), 343-353.
143. R. Stanislaus, A.K. Singh and I. Singh, Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis, J. Neurosci. Res. 66 (2001), 155-162.
144. R. Stanislaus, A.G. Gilg, A.K. Singh and I. Singh, Immunomodulation of experimental autoimmune enephalomyelitis in the Lewis rats by Lovastatin, Neurosci. Lett. 333 (2002), 167-170.
145. D. Steinberg, S. Parthasarathy, T.E. Carew, J.C. Khoo and J.L. Witztum, Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. [see comment], N. Engl. J. Med. 320 (1989), 915-924.
146. M. Takemoto and J.K. Liao, Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors, Arterioscler. Thromb. Vasc. Biol. 21 (2001), 1712-1719.
147. S. Tartakover-Matalon, N. Cherepin, L. Drucker, A. Fishman, M. Pomeranz and M. Lishner, Simvastatin has deleterious effects on human first trimester placental explants, Hum. Reprod. 20 (2005), 2866-2872.
148. D. Tsuchiya, S. Hong, Y. Matsumori, H. Shiina, T. Kayama, R. A. Swanson, W.H. Dillman, J. Liu, S.S. Panter and P.R. Weinstein, Overexpression of rat heat shock protein 70 is associated with reduction of early mitochondrial cytochrome C release and subsequent DNA fragmentation after permanent focal ischemia, J. Cereb. Blood Flow Metab. 23 (2003), 718-727.
149. C. Urbich, E. Dernbach, A.M. Zeiher and S. Dimmeler, Double-edged role of statins in angiogenesis signaling, Circ. Res. 90 (2002), 737-744.
150. M.R. VanNewkirk, M.B. Nanjan, J.J. Wang, P. Mitchell, H.R. Taylor and C. A. McCarty, The prevalence of age-related maculopathy: the visual impairment project, Ophthalmology 107 (2000), 1593-1600.
151. C.J. Vaughan, M.B. Murphy and B.M. Buckley, Statins do more than just lower cholesterol, Lancet 348 (1996), 1079-1082.
152. C.J. Vaughan and N. Delanty, Neuroprotective properties of statins in cerebral ischemia and stroke, Stroke 30 (1999), 1969-1973.
153. C.J. Vaughan, Prevention of stroke and dementia with statins: Effects beyond lipid lowering, Am. J. Cardiol. 91 (2003), 23B-29B.
154. T. Vinding, M. Appleyard, J. Nyboe and G. Jensen, Risk factor analysis for atrophic and exudative age-related macular degeneration. An epidemiological study of 1000 aged individuals, Acta Ophthalmol. (Copenh). 70 (1992), 66-72.
155. Y. Vodovotz, M.S. Lucia, K.C. Flanders, L. Chesler, Q.W. Xie, T.W. Smith, J. Weidner, R. Mumford, R. Webber, C. Nathan, A.B. Roberts, C.F. Lippa and M.B. Sporn, Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease, J. Exp. Med. 184 (1996), 1425-1433.
156. T. Vollmer, L. Key, V. Durkalski, W. Tyor, J. Corboy, S. Markovic-Plese, J. Preiningerova, M. Rizzo and I. Singh, Oral simvastatin treatment in relapsing-remitting multiple sclerosis, Lancet 363 (2004), 1607-1608.
157. M.J. Wagstaff, Y. Collaco-Moraes, J. Smith, J.S. de Belleroche, R.S. Coffin and D.S. Latchman, Protection of neuronal cells from apoptosis by Hsp27 delivered with a herpes simplex virus-based vector, J. Biol. Chem. 274 (1999), 5061-5069.
158. X. Wang, H. Tokuda, D. Hatakeyama, K. Hirade, M. Niwa, H. Ito, K. Kato and O. Kozawa, Mechanism of simvastatin on induction of heat shock protein in osteoblasts, Arch. Biochem. Biophys. 415 (2003), 6-13.
159. J.L. Wang, D.S. Ke and M.T. Lin, Heat shock pretreatment may protect against heatstroke-induced circulatory shock and cerebral ischemia by reducing oxidative stress and energy depletion, Shock 23 (2005), 161-167.
160. S. Warshafsky, D. Packard, S.J. Marks, N. Sachdeva, D.M. Terashita, G. Kaufman, K. Sang, A.J. Deluca, S.J. Peterson and W.H. Frishman, Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke, J. Gen. Intern Med. 14 (1999), 763-774.
161. C. Weber, W. Erl, K.S. Weber and P.C. Weber, HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia, J. Am. Coll. Cardiol. 30 (1997), 1212-1217.
162. G. Weitz-Schmidt, K. Welzenbach, V. Brinkmann, T. Kamata, J. Kallen, C. Bruns, S. Cottens, Y. Takada and U. Hommel, Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site, Nat. Med. 7 (2001), 687-692.
163. H.L. Wilson, D.M. Schwartz, H.R. Bhatt, C.E. McCulloch and J.L. Duncan, Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. [see comment], Am. J. Ophthalmol. 137 (2004), 615-624.
164. B. Wolozin, W. Kellman, P. Ruosseau, G.G. Celesia and G. Siegel, Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors, Arch. Neurol. 57 (2000), 1439-1443.
165. D. Woo, B.M. Kissela, J.C. Khoury, L.R. Sauerbeck, M.A. Haverbusch, J.P. Szaflarski, J.M. Gebel, A.M. Pancioli, E.C. Jauch, A. Schneider, D. Kleindorfer and J.P. Broderick, Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study, Stroke 35 (2004), 1360-1364.
166. S. Wyatt, C. Mailhos and D.S. Latchman, Trigeminal ganglion neurons are protected by the heat shock proteins hsp70 and hsp90 from thermal stress but not from programmed cell death following nerve growth factor withdrawal, Brain Res. Mol. Brain Res. 39 (1996), 52-56.
167. C. Xiao, S. Chen, M. Yuan, F. Ding, D. Yang, R. Wang, J. Li, R.M. Tanguay and T. Wu, Expression of the 60 kDa and 71 kDa heat shock proteins and presence of antibodies against the 71 kDa heat shock protein in pediatric patients with immune thrombocytopenic purpura, BMC Blood Disord. 4 (2004), 1.
168. H. Yasuda, H. Shichinohe, S. Kuroda, T. Ishikawa and Y. Iwasaki, Neuroprotective effect of a heat shock protein inducer, geranylgeranylacetone in permanent focal cerebral ischemia, Brain Res. 1032 (2005), 176-182.
169. M.I. Yilmaz, Y. Baykal, M. Kilic, A. Sonmez, F. Bulucu, A. Aydin, A. Sayal and I.H. Kocar, Effects of statins on oxidative stress, Biol. Trace Elem. Res. 98 (2004), 119-127.
170. A. Yilmaz, C. Reiss, O. Tantawi, A. Weng, C. Stumpf, D. Raaz, J. Ludwig, T. Berger, A. Steinkasserer et al., HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis, Atherosclerosis 172 (2004), 85-93.
171. B.C. Yoo, R. Seidl, N. Cairns and G. Lubec, Heat-shock protein 70 levels in brain of patients with Down syndrome and Alzheimer's disease, J. Neural Transm. Suppl. 57 (1999), 315-322.
172. B.C. Yoo, S.H. Kim, N. Cairns, M. Fountoulakis and G. Lubec, Deranged expression of molecular chaperones in brains of patients with Alzheimer's disease, Biochem. Biophys. Res. Commun. 280 (2001), 249-258.
173. S. Youssef, O. Stuve, J.C. Patarroyo, P.J. Ruiz, J.L. Radosevich, E.M. Hur, M. Bravo, D.J. Mitchell, R.A. Sobel, L. Steinman and S.S. Zamvil, The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease, Nature 420 (2002), 78-84.
174. P. Zandi, D.L. Sparks, A.S. Khachaturian, J. Tschanz, M. Norton, M Steinberg, K.A. Welsh-Bohmer and J.C. Breitner, Cache County Study investigators, Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study, Arch. Gen. Psychiatry 62 (2005), 217-224.